Introduction
Complete and unbiased knowledge disclosure is widely believed to support the advancement of science by allowing scientists to verify past research, to replicate prior studies, and to access knowledge which may enhance opportunities for new research (Merton 1973, Dasgupta and David 1994) . Yet, there is ample evidence that full and unbiased dissemination of data and findings may not be the ordinary outcomes of many research projects (Fanelli 2010, Andreoli-Versbach and Mueller-Langer 2014) . Against this background, this study sets to explore selective reporting, defined as the publication of only part of the findings originally recorded during a research study, based on the results (e.g., whether or not such findings are significant for the study investigators). The particular concern with selective reporting is that if results are selectively withheld based on their direction, then systematic biases are introduced in the final research publication.
This study examines selective reporting using data on clinical research projects. Clinical research is an apt setting for exploring selective reporting for various reasons. Firstly, the thorough revision of published studies is at the very heart of evidence-based medicine; thus most extant research on publication and bias has been conducted in the biomedical sciences (Guyatt, Cairns et al. 1992 , Oxman and Group 2004 , Atkins, Briss et al. 2005 , Guyatt, Oxman et al. 2008 . Secondly, conversations on clinical trials' data transparency have gained momentum lately, following several instances of large scale scientific mistakes or deliberate misconduct -see for example Goldacre (2012) . Third, the consequences of bias in clinical research are particularly serious. In the words of a topical editorial in The Economist discussing clinical research (Economist 2015) , "[the bias in publication] at best, has produced a polluted evidence base" and "at worst, the skew has caused demonstrable harm [to patients and volunteers in clinical trials]".
Despite ample empirical confirmation of the widespread occurrence of selective reporting, the evidence on the correlates of selective reporting is scarce. Insights into publication bias are generally derived from surveys of researchers, with the obvious limitations of self-reporting (Chan and Altman 2005) . Further suggestions are provided by the analysis of prominent cases, concerning for example scientists being caught misrepresenting their research results. Such cases, while suggestive, are likely to capture only the tip of the iceberg and may be of limited value for policy and prevention.
Starting from this evidence, this study attempts to generate insights into the factors associated to selective reporting. Specifically, this paper sets to explore whether or not the (incidence) of selective reporting correlates with two salient characteristics of the clinical research project: (1) the source of institutional support and (2) the type of innovation evaluated.
To tackle these issues, this study employs a unique hand-collected sample using the information and the evidence ratings presented in the reviews compiled by the Cochrane Collaboration, the leading organisation in the field of provision of informed medical decisions (Jadad, Cook et al. 1998) . Although the use of ratings systems and the promotion of systematic reviews have been major focuses of evidence-based medicine (Guyatt, Cairns et al. 1992 , Oxman and Group 2004 , Atkins, Briss et al. 2005 , Guyatt, Oxman et al. 2008 ), I am not aware of prior research investigating the correlates of selective reporting using this data and approach.
To summarise, in this paper I seek to provide novel empirical evidence regarding project-level characteristics that may correlate with the likelihood of selective reporting. The results of the present study show that (the receipt of) industry funding correlates positively with selective reporting; however this effect is restricted to studies where at least one author is affiliated to industry. In addition, the analysis of the relationship between the type of innovation and selective reporting indicates that the chances of selective reporting are higher for projects exploring radical innovation, compared to projects investigating incremental innovation. Taken together, these findings support the view that the likelihood medicine. Several safety scandals have challenged the assumption that all prescribed drugs have been subject to close scrutiny -notable examples include Vioxx (Horton 2004) 
and Tamiflu (Smith 2009).
A crucial matter recognised by the debate on the quality of clinical research evidence is that of transparency and access to clinical trial data. Although trials need to be registered and their results have to be published in trials registries, enforcing these legislations has proved quite difficult (Zarin, Tse et al. 2011 ).
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Because of its impact on the ability for researchers to verify study results, the issue of trial data release has been given a lot of attention in recent months by academics and consumer groups (e.g., the AllTrials campaign in the UK). Concerns about the lack of unbiased information have also been expressed by company shareholders. In July 2015, a group of investors teamed up with AllTrials to pressure drug makers to disclose clinical trial data (Economist 2015).
Selective reporting in clinical research
Although trial data can be disclosed in several ways (e.g., in trial registries), the peer-review system still holds its original function to certify research results (Merton 1973) and writing manuscripts for publication remains a fundamental component of clinical research. As far as publication in academic journals is concerned, a profusion of statistically significant, "good" published results has long been acknowledged by the scientific and medical community. Far from giving any optimistic interpretation e.g., on the efficacy of research, scholars have identified several publication practices that directly contribute to the skewness of printed results.
First of all, researchers may simply decide against publication of entire studies, based on whether or not the results are "positive". This practice, concerning the entire suppression of a research paper, has been termed selective publication (Ross, Tse et al. 2012) . Estimates indicate that the results of half of clinical trials are never published (Bekelman, Li et al. 2003 , Lexchin, Bero et al. 2003 , Dwan, Altman et al. 2008 , Lee, Bacchetti et al. 2008 , McGauran, Wieseler et al. 2010 , Song, Parekh et al. 2010 , Riveros, Dechartres et al. 2013 ).
In addition, even for those studies that reach publication, only part of the original research findings may be included in the published paper version, a practice that is referred to as selective reporting. More specifically, the term selective reporting has been used to indicate the selection of a subset of research findings, on the basis of their direction, for publication in academic journals (Hutton and Williamson 2000, Higgins, Green et al. 2008) . The most recent systematic review of the empirical evidence of publication bias and selective reporting (Dwan, Gamble et al. 2013 ) discusses the Registration in a clinical trial registry has been enforced only in relatively recent times. For example, in the USA the creation of the ClinicalTrials.gov registry was authorised in 2000. In 2007, the FDA expanded this mandate by requiring sponsors of applicable clinical trials to register and report basic results at ClinicalTrials.gov. increasing proportion of studies in which at least one outcome is changed or omitted, with some analyses concluding that up to 62% of the investigated trials had major discrepancies in the outcomes.
Selective reporting has received a lot of attention in clinical research (Chan, Hróbjartsson et al. 2004 , Chan and Altman 2005 , Dwan, Altman et al. 2008 . Two main themes emerge from these studies:
(1) selective reporting is a potential threat to the validity and reliable of research; and (2) bias can be introduced in many ways and it is difficult to detect.
The central point to note in the definition of selective reporting is that the publication of a study's findings or, rather, the lack of it, is influenced by the direction and statistical significance of these findings. In other words, "negative" or "null" outcomes have lower chances of being reported. As a consequence, selective reporting is a source of bias, i.e. it introduces systematic errors in the study results. Accordingly, selective reporting has been discussed in the context of research misconduct together with other forms of misbehaviour such as data fabrication and plagiarism. One can clearly envision that the implications of selective reporting are particularly serious in clinical research: efficacy of a treatment may be overestimated or, even more concerning, the adverse reporting of a treatment may be underestimated. For example, selective serotonin reuptake inhibitors (SSRIs) were reported to exhibit safety and efficacy for treatment of depression in children and adolescents; reanalysis of unpublished findings raised alerts regarding higher suicidal ideation rates in this population (Sharp and Hellings 2006) . Financial damage can also be done, as proved by the Tamiflu case (Smith 2009).
Trial publications may be subject to different types of selective reporting. For example, the effects of a drug on certain outcome variables may be recorded but entirely excluded from publication (Tannock 1996) . 2 Additionally, papers may discuss only one of the several different ways in which an outcome can be operationalised (e.g., continuous or binary) or gathered (for example from a subset of observations). More subtly, the descriptions of outcomes as 'primary' or 'secondary' can be altered retrospectively in the light of the findings (Chan, Hróbjartsson et al. 2004) . Selective reporting may also refer to the inadequate reporting of a drug's adverse events (Melander, Ahlqvist-Rastad et al. 2003) or to misreporting of statistical methods. Due to these heterogeneities, and because much of what is unpublished is unobserved, the detection of selective reporting is not straightforward. Compared to other disciplines, the acknowledgement of selective reporting is somehow less problematic in clinical research, because distinctive procedures are in place. Detailed description of the study objectives and intended outcomes may be available in trial protocols or trial registries, official catalogues for recording clinical studies. Thus, selective reporting can be detected by comparing the published report against the research protocol and/or the clinical trial registry record.
Clinical trials typically involve assessing the effects of a drug on certain outcome variables. For example, in a study evaluating the benefits of a treatment for a cold, the outcome of interest may be "number of days with cold symptoms".
Emerging evidence on the correlates of selective reporting
In this study, I ask the following question about selective reporting: Are specific factors systematically associated with (the incidence) of selective reporting? Although the pervasiveness and importance of selective reporting has been discussed in many studies, the evidence on the factors associated to selective reporting is limited. Past works largely rely on self-reported data from surveys of researchers, which may be subject to bias and not provide suitable foundations for prevention or policy. Few empirical studies (Chan, Hróbjartsson et al. 2004 , Chan and Altman 2005 , Smyth, Kirkham et al. 2011 ) describe the reasons why outcomes are not reported: these include lack of clinical importance and lack of statistical significance.
To frame my analysis I consider my research question in the context of past literature and focus on two salient characteristics of research projects: (1) the source of institutional support; and (2) the type of innovation evaluated.
Relationship between source of institutional support and selective reporting
In response to technological and commercial opportunities, industry support of biomedical research has increased dramatically over the past 50 years. Life science companies are more and more involved with academia, and a variety of financial interactions exists, ranging from academic institutions receiving industry funding, to personal financial ties with industry sponsors. Private institutions are also increasingly contributing to scientific discourse via publications in peer-reviewed journals and their outputs are often of a high standard and widely cited (Koenig 1983 , Hicks 1995 , Lim 2004 ).
This well documented increase in industry-involvement is raising concerns related to its effect on the quality of published research (Bekelman, Li et al. 2003) , considering that firms have not only the motivations but also the means to stay in control of the outcomes of the publication process.
In the pharmaceutical sector specifically, many studies have examined the motivations that lead firms to publish (Cockburn and Henderson 1998 , Zucker, Darby et al. 2002 , Gittelman and Kogut 2003 .
The publication of clinical trial results in academic papers is an important means for firms to communicate the benefits of approved compounds to prescribers and regulators (Azoulay 2002, Polidoro and Theeke 2012) . Publishing positive results can help ensure that a treatment will be approved by the regulator and may translate in wider use of a new product. On the other hand, negative results can put an end to the development of a new drug or reduce its market uptake Available evidence suggests that when firms make their research findings available in scientific journals, they indeed try to stay in control of the outcomes of the publication process (Gotzsche, Hróbjartsson et al. 2007 , Sismondo 2008 . Blumenthal, Campbell et al. (1996) found evidence of both publication delay and nondisclosure restrictions, with reasons for not publishing including "to delay the dissemination of undesired results". Bekelman, Li et al. (2003) found that industry funding is associated with limitations on data access or publication of results. Czarnitzki, Grimpe et al. (2014) found a strong positive relationship between the degree of publication restrictions and the share of industry sponsorship.
The relationships between industry funding and bias in publication, has been analysed extensively in recent years, particularly in medical research: the results are mixed. Several studies have found that industry-sponsored studies are more likely to report favourable or significant outcomes compared to privately-funded studies, see for example (Bekelman, Li et al. 2003 , Lexchin, Bero et al. 2003 , Schott, Pachl et al. 2010 , Song, Parekh et al. 2010 , Lundh, Sismondo et al. 2012 . Taken together, the mechanisms underlying the prevalence of positive outcomes in industry trials remain to be fully understood: reporting bias is one of several possible explanations. Recent works suggest that in determining the potential role of the funding source on non-publication, it is important to discriminate between different forms of support and disentangle the effect of funding from authorship (Ahn, Woodbridge et al. 2017) . Regarding selective reporting specifically, the most comprehensive and recent review of the available evidence (Dwan, Gamble et al. 2013) concludes that although funding is an important factor to consider when investigating reporting bias, there are no definite results on the relationship between industry involvement and selective reporting.
This brief literature review indicates that findings are mixed with regard to the relationship between industry involvement and bias in scientific publication. While there is some evidence of an association between industry involvement and reported findings, the effect of funding source on bias seems to be unclear and speculative.
Relationship between type of innovation and selective reporting
The association with private institutions is one among many features of clinical research projects and we can expect that industry involvement is not the only factor that may create challenges for the complete and unbiased reporting of research results. In particular, it seems reasonable to question whether different pressures or difficulties may arise for investigators based on whether the technologies evaluated are more or less novel. However, little is known about whether the type of innovation investigated in a research project may associate with bias in reporting. A better understanding of this issue is important for two reasons. Firstly, it would be interesting to know whether the pursuit of innovation comes at a price of increased bias in study conclusions. Secondly, if selective reporting is associated with specific types of research, then many policy initiatives that encourage research transparency in general, might be re-aligned to take into account the diverse nature of the research projects.
To my knowledge, no studies have specifically examined possible associations between the novelty of the technology evaluated and selective reporting. The literature on misconduct indicates several factors that are hypothesised to increase scientists' propensity to falsify research, including: likelihood of being caught and consequences of being caught, pressures to publish and competition for research funding (Lacetera and Zirulia 2011). The analysis of these factors leads to contradictory predictions on whether selective reporting is most likely to occur in projects exploring ground-breaking innovation, compared to those exploring incremental innovation.
For example, the work of Lacetera and Zirulia (2011) suggests that there may be a mismatch between the type of research that is more likely to be fraudulently produced (incremental) and the type of research that is more likely to be caught if fraudulent (radical).
Considering pressures to publish, it is not clear whether these are more intense in radical as opposed to incremental research. On one hand, if the value of a published article (e.g., in term of citations) is higher for ground-breaking research, incentives to highlight positive findings and alter or remove negative results may be stronger compared to incremental research. On the other hand, given that academic journals pursue the publication of "hot new findings'' (Witten and Tibshirani 2012), novel research may have higher chances of being published, making it more pressing for investigators involved in incremental research to engage in partial reporting to increase the chances of publication.
Outright scientific misconduct is not the only determinant of bias in publication (Fanelli 2010).
First, the likelihood of altering or removing study results may depend on the probability that a research study reaches findings that are negative or insignificant. It is unclear how this probability may vary based on the type of innovation investigated. Incremental research by definition relies on a great amount of prior information, thus failure rates should be lower. In biomedical research, for example, development programs are more risky for novel drugs compared to drugs that have therapeutic qualities similar to those of an already marketed drug. However, prior knowledge in incremental research may also have the effect of increasing scientists' confirmation bias (a tendency to seek confirming evidence) and theory tenacity (persistent belief in a theory in spite of contrary evidence) (Loehle 1987).
In addition, the chances of misreporting may depend on the rigour of research methodologies (including the flexibility in definitions, analysis and interpretation of research). In studies that address novel phenomena, the connection between theories and findings could be more open to interpretation.
This would give scientists more freedom in deciding how to interpret data, which increases the chances that they will support the hypotheses they believe to be true ( The studies referred to above show that while the type of research undertaken or its topic may have an influence on what gets published, predictions on where poor reporting is more likely (e.g., where manipulation of data and result is more frequent) are often conflicting and they have been empirically verified by very few studies.
Data source and measures

Data sources
The literature reviewed above indicates that prior work on the correlates of reporting bias was complicated by, among others by: (1) limitation of the data (most previous studies have been limited to one specialty, drug type, or journal); and (2) the lack of a standardized methodology for the assessment of bias. To attempt to tackle these issues, this study entailed an extensive data collection effort and relies on a unique hand-collected dataset that leverages expert-driven ratings of selective reporting.
My main source of information on clinical papers, including their selective reporting rating, was the Database of Systematic Reviews maintained by the Cochrane Collaboration. The Cochrane Collaboration is an international not-for-profit association leading in the field of the provision of systematic reviews used to inform healthcare decisions. The work of the Cochrane Collaboration has been fundamental with regard to the promotion of systematic reviews and the shift to evidence-based medicine (Guyatt, Cairns et al. 1992 , Guyatt, Cook et al. 2004 ). In the words of a professor of medicine quoted in a recent New York Times article, "When clinicians are debating the right thing to do, all someone needs to say is, 'There's a Cochrane review about that,' and the argument ends" (Sepkowitz 2014). Cochrane reviews describe the methodological quality of all appraised trials focusing on five characteristics that may introduce a risk of bias in the study results: (1) adequate sequence generation;
(2) adequate measures to conceal allocation; (3) blinding; (4) completeness of outcome data; and (5) selective reporting -the key dimension considered in my analysis. A "traffic-light" representation is then provided for each study, where green indicates a low risk of bias, amber an unknown bias risk and red a high risk of bias.
In order to build a comprehensive dataset, I started by investigating all the titles registered with the Cochrane Review Groups covering seven therapeutic areas: Endocrinology, Respiratory, Infectious Diseases, Cardiology, Oncology, Mental Health and Dermatology. My search strategy generated 764 reviews, of which I identified 73 for inclusion. 4 The included reviews appraised 1,839 clinical trials.
For each trial, Cochrane reviews listed one or more publications reporting the trial results. In order to build a dataset of projects univocally paired to scientific papers, in case of multiple publications I linked to each trial the reference that most closely resembled the trial code name used in the Cochrane review Duplicates, trials that were not matched to a published paper (e.g., conference abstracts and posters) and studies with no selective reporting rating were then removed from the selection, leaving 1,068 clinical trial/publication pairs. For these studies I extracted the risk of bias rating assigned by Cochrane and any additional study information. Due to the lack of a standardised reporting format across reviews, cleaning the data and matching the relevant trial information to construct a structured dataset entailed a considerable effort.
I extended the data in three directions. First, I used SCOPUS to collect bibliometric data for the full set of trial publications. I was specifically interested in extracting information about authors' affiliations. 39 (4%) publications were not retrieved in SCOPUS, resulting in a total of 1,029 articles for the final sample. Because drugs can be approved in several dosages and they can have different formulations I made an effort to match the FDA's approval record corresponding to the precise dosage/formulation investigated in each trial. Studies concerning (1) biologics, (2) vaccines, (3) nondrug interventions and (4) long established drugs (approved before 1982) were excluded because reporting requirements in the FDA databases are different. For the drugs that were retrieved in the FDA's database, I collected the assigned chemical type (e.g., whether or not the approved NDA was for a New Molecular Entity) and therapeutic significance rating (e.g., P for priority reviews drugs). I was also interested in checking whether each drug was specifically approved for the indication(s) investigated in the studies included in my sample and whether these were the first or subsequent indications approved. To collect this information, I read approval letters (for never-before-approved drugs) as well as any efficacy supplements (for drugs approved for new uses).
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From the initial list of 1,029 publications included in the dataset, the matching process identified 471 papers investigating 78 drugs approved by the FDA in the specific formulations and indications investigated in the included trials. The remaining trials include: 226 studies that were excluded because reporting requirements in the FDA databases are different (e.g., biologics); 195 studies concerning drugs that could not be retrieved in the FDA approval dataset (e.g., drugs that are not approved by the FDA); and 137 studies where I was unable to identify the focal drug or resolve ambiguities regarding the specific indication/patient population under study.
Measures
To operationalize selective reporting in my analysis, I relied on data collected from the Cochrane Library. I created a binary variable ('Selective Reporting') set to 1 when the Cochrane reporting rating indicated high risk of bias from selective reporting and 0 otherwise (unknown or low risk of bias from selective reporting).
To examine the correlates of selective reporting, I identified and developed the following independent variables.
Source of institutional support. In this study I explored both (1) direct funding and (2) personal financial interests.
To identify the source of funding (industry as opposed to non-industry) I considered statements of sources of support and acknowledgments declared in the individual publications (e.g., "trial funded by industry", "trial sponsored by industry" "financial support received from a pharmaceutical company", "unrestricted educational grants"). Accordingly, I distinguished between studies wholly or partially funded by industry ('Industry') and studies funded independently of industry ('Non-Industry').
The remaining studies, that lacked sufficient information on funding to be categorised as funded by 7 A relatively small number of efficacy supplements for new indications are submitted via a full original new drug application (type 6 NDA). All others efficacy supplements are submitted as supplements to original NDAs (supplemental NDAs). Approval letters are publicly available at http://www.accessdata.fda.gov/ industry or other sources, fell into two groups: studies explicitly reporting no funding ('None Declared') and studies with no funding information reported ('Not Reported').
In line with past studies e.g., (Perlis, Perlis et al. 2005) , I defined financial interests as any report of consulting or speaking fees, stock ownership, or employment by a firm. However, I also inferred financial interests where no disclosure was made, but the study authors were affiliated to a pharmaceutical company. Specifically I considered whether or not: (1) at least one author had a professional affiliation to a pharmaceutical company ('Employment'); (2) at least one author had declared a personal financial interest including: consulting or speaking fees, stock ownership ('Other Financial Associations'); and (3) the study included provision of study medication ('Donation of Medication').
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Type of innovation. An attractive characteristic of pharmaceutical research is that an objective classification system for innovation is provided by the US regulator.
On the basis of the drug composition of new applications, the FDA distinguishes between (1) New Molecular Entities (NMEs) and (2) incrementally modified drugs, which modify an existing drug to use it in improved formulations or other indications. Given that NME status is the most commonly adopted measure of innovation e.g., the more NMEs approved by the FDA in a given year, the more innovation in the industry (Kesselheim, Wang et al. 2013) , I started by investigating whether or not a trial was evaluating a NME ('NME'=1 if the drug is New Molecular Entity).
In addition, depending on the therapeutic potential of new drug applications, the FDA also separates Priority and Standard review applications. Accordingly, I distinguished between (1) NME that also received Priority status ('Priority NME') and (2) NME that only received Standard review designation ('Standard NME).
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To account for a number of factors that might confound my exploration of the correlates of selective reporting, several control variables were added to the model at the level of: the trial; the article; the Cochrane review; and the research area.
First, I collected data on characteristics of trials that could influence bias. These include study size ('Participants', the natural log transformation of the number of enrolled participants), duration ('Weeks', the log transformation of the number of weeks), choice of comparator ('Placebo', 1= trial was placebo-controlled) and blinding ('Blinding Bias', 1 = trial was rated as at high risk of bias due to blinding in the Cochrane reviews).
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I also considered the risk of bias ratings along the remaining three dimensions assessed by Cochrane ('Any Other Bias', 1= trial was rated as at high risk of bias in at least one of the reported dimensions e.g., adequate sequence generation, adequate measures to conceal allocation and completeness of outcome data).
Given that the quality of a study may be associated with publication in a high impact journal (Lee included the log transformation of the count of the affiliations of the article ('Affiliations').
To capture methodological differences in the Cochrane appraisal system over time, I distinguished the most recent reviews ('Reviewed After 2012'=1) from the ones published before 2012.
Finally, to account for differences across scientific fields, I included dummies at the level of the seven therapeutic areas ('Oncology', 'Mental Health', 'Infectious Diseases', 'Cardiology', 'Endocrinology', 'Respiratory' and 'Dermatology').
Modelling strategy and results
10 With regard to trial duration, unfortunately, in over one third of cases the trial duration was either missing from the characteristics reported in the Cochrane review or it was just provided as a range e.g. 8 to 26 weeks. In these cases, duration was estimated using the mean duration for the trials in my dataset investigating the same condition (where duration was missing) or the median point of the given range (e.g. 16 weeks for the '8 to 26 weeks' range). I created an indicator variable ('Duration Estimate') to flag these instances. With regard to blinding, I compared the Cochane risk of blinding bias variable with an alternative measure of blinding derived from my own review of trial characteristics: reassuringly, the correlation was very high. Also, all logarithmic transformations used a natural logarithm.
Descriptive statistics
Descriptive statistics of the variables for the full dataset (1,029 papers used for the first analysis on the relationship between institutional support and selective reporting) are given in Table 1 . Selective reporting was identified in 21.7% of the trials in the sample. The majority of the studies (59.4%) received industry funding and just over half of all papers (51.4%) have at least one author with some personal financial interests. T-tests show that, in the sample considered, industry funded projects are broadly of better methodological quality (e.g., they are more likely to be of a bigger size and to have a longer duration), compared to trials receiving funding from other sources and to trials with no funding declared or reported. These results are consistent with past research indicating that privately-funded studies may have different characteristics compared to publicly-funded trials (Djulbegovic, Lacevic et al. 2000 , Procyshyn, Chau et al. 2004 . T-tests also show that there are no substantial differences between industry and non-industry funded trials in the sample with regard to year of publication and journal quality. Reflecting a general evolution over time towards better reporting of funding information, 11 trials with no funding reported tend to be older and to be published in lower quality journals compared to the studies that include funding information.
The basic descriptive statistics for the sub-sample of 471 studies used for the second analysis on the relationship between type of innovation and selective reporting are presented in Table 2 . The vast majority of the trials included in this sample evaluated New Molecular Entities (64.5%). About one in four of these trials investigated drugs that also received a priority rating ('Priority NMEs'=1 for 15.7% of the sample). Due to the exclusion criteria discussed earlier, this sample is highly selected.
Nevertheless, the comparison of the 471 included papers against the 558 papers that I have removed shows that the trials included in the sub-set are broadly of similar methodological quality to the others (t-test showed no significant difference in the journal JCR score or in the choice of comparator). In addition, selective reporting is more frequent in this sample (23.3% of trials in the sub-sample compared to 20.4% of the remaining trials), however a test of proportions shows that this difference is not significant. Finally, the 471 trials in the sub-set are more likely to have industry funding compared to the 558 removed papers Simple correlations between my explanatory variables in both the full and the sub-sample are not distinctly high. However, to guard against multicollinearity, I calculated the variance inflation factor (VIF) for all variables in both samples. None of the obtained VIFs were above the concerning value of 10 (Neter, Kutner et al. 1996). 12 These are related to of a number of interventions to increase transparency, for example the CONSORT 2010 Statement.
12 For brevity, the results are not reported here. However, these are available upon request.
Industry involvement and selective reporting
To explore the relationship between source of institutional support and selective reporting, I have used the whole sample of trials (n=1,029). As my dependent variable ('Selective Reporting') is binary, I applied a logistic regression model. Since the observations where derived from different Cochrane reviews, compiled by different authors, standard errors were clustered by reviewer. For each review, I considered the first author listed, which left me with 48 clusters.
In Table 3 i.e. predict a low chance of selective reporting. The larger the study size, the lower the probability that selective reporting occurs in the published paper reporting the study results. On the other hand, as expected, the coefficient of 'Any Other Bias' is positive and significant, indicating that selective reporting is more likely if a trial is at high risk of bias due to any of the other risk dimensions assessed by Cochrane. Interestingly, the number of papers associated to a trial is also strongly and positively correlated with the chances of selective reporting. A possible explanation for this result is that bias in general is more likely when multiple publications are produced from a single study. For example, prior work shows that studies with significant results are more likely to appear in multiple publications (Easterbrook, Gopalan et al. 1991) . Given that past works have described the difficulties and frustration caused by the 'disaggregation' of medical research when results are presented in several publications (Huston and Moher 1996), we cannot exclude that higher bias ratings reflect the difficulties faced by Cochrane reviewers when trying to make sense of data disaggregated in several publication.
Finally, the coefficients of field-level dummies indicate that selective reporting is more likely in Mental Health and Dermatology trials, compared to Oncology trials (reference category, removed). The model results, and in particular the high incidence of selective reporting in Mental Health, a field that is generally considered "soft" because research is mainly determined by non-cognitive factors as opposed to data and theories, are intuitively consistent with the hypothesis -see for example Fanelli (2010) -that bias is more common in "softer" sciences.
Columns (2) - (5) report the results for different specifications of the model. Column (2) explores the role of the source of funding. The results indicate that selective reporting is more likely in industry funded projects, compared to projects funded by others institutions (reference category, removed).
Columns (3) -(4) explore the role of personal financial interests. I tried two different specifications that consider any financial interests (Column 3) or specific types of financial interests.
The results show that employment alone (i.e. the presence of one or more company employees amongst the study authors) is significantly associated with selective reporting. In Column (5) I interact Industry Funding and Employment. The results indicate that the significance of Industry funding for selective reporting is restricted to those projects that receive direct funding and have at least one author that is a firm employee. Industry affiliation alone ("Employment Only") is not significantly correlated to selective reporting. However, only a very limited number of trials in the sample have an industry affiliation and public funding, therefore we cannot draw any solid conclusions about the effect of authorship alone.
Type of innovation and selective reporting
To assess the impact of the type of innovation, I used my smaller sample including only those trials where I could identify the focal drug that was FDA approved for use in the indication(s) investigated in the trial dataset (n=471). Table 4 summarises the results for five different model specifications. Column (1) reports the baseline model. Column (2) includes the variable 'NME', capturing whether or not a trial is evaluating a New Molecular Entity. The results show no significant difference in the incidence of selective reporting in projects investigating New Molecular Entities compared to those investigating incrementally modified drugs. In Column (3) I stratify the trials exploring NMEs based on the drugs' FDA therapeutic rating (priority or standard review). The coefficient of 'Priority NME' is positive and significant, indicating that selective reporting is more likely when research projects investigate Priority NME drugs compared to incrementally modified drugs (reference category, removed). Column (4) includes the interaction between source of funding and personal interests (tested in the first part of the analysis). The coefficient of 'Industry Funding and Employment' is still positive and significant, confirming that my results for the full model are robust to changes in the sample (e.g., restricting to the sub-sample). Column (5) reports all the variables. The sign and significance of the coefficient of Priority NME is unchanged after the introduction of the industry support variables.
In robustness checks, I re-estimated my core model, excluding those records where selective reporting rating was "unknown". In other robustness checks, I removed the variable "Published after 2007" and added year dummies. In such models, which I do not report in the paper, my main results are largely unchanged.
Discussion and conclusion
Although several studies have tried to assess the prevalence of selective reporting in clinical trials, very few studies to date have explored the factors associated to selective reporting empirically. This paper takes a first step to filling this gap, by examining a sample of clinical trials in seven therapeutics areas and leveraging the information contained in the Cochrane reviews.
Discussion of source of funding and selective reporting
The first aim of this study was to test the relationship between the source of institutional support and selective reporting. Within my sample, the odds of selective reporting are 1.6 higher for industryfunded compared to studies funded by other institutions. In the stratified analysis, industry funding was significantly associated with selective reporting only for studies where one or more authors had an employee relationship with a pharmaceutical company (odds ratio=2.07, baseline category: privately Finally, disclosures may influence authors' conclusions and readers' perceptions. For example, disclosures may compromise it further through moral licensing, 'the often unconscious feeling that biased advice is justifiable because the advisee has been warned' (Loewenstein, Sah et al. 2012 ).
Likewise, we cannot exclude those disclosures may also influence reviewers' perceptions of the validity of published studies (Schroter, Morris et al. 2004) van Lent et al. refer to the ICH-GCP (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use -Good Clinical Practice) guidelines, defining study sponsor as "an individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial."
Discussion of type of innovation and selective reporting
The second objective of this study was to examine the relationship between the type of innovation and selective reporting. The findings suggest that the likelihood of selective reporting is higher for trials exploring Priority NMEs drugs compared to trials investigating incrementally modified drug. There could be many explanations for these results.
First, in line with (Sorescu, Chandy et al. 2003) and Sternitzke (2010) , Priority NME drugs can be considered radical innovations i.e. they represent both a technological and market improvement over existing treatments. It might be that only ground-breaking projects bring high enough benefits (or high enough risks of failure) to justify resorting to selective reporting. This interpretation contrasts with some existing literature on misconduct e.g., with (Lacetera and Zirulia 2011)'s prediction that fraud is more likely in incremental rather than radical research. Looking at scientists' abilities, it may also be the case that blue-sky explorations are conducted by researchers that are more talented, and in turn more capable of altering research results and engaging in poor reporting. Considering that priority rated drugs have the potential to treat diseases where current treatment is limited, it may also be the case that the potential high social repercussion of Priority drugs offers considerable latitude for rationalization of substandard reporting practices. Also, Priority review designation means that the FDA aims to take action on a drug application within 6 months, compared to 10 months under Standard review. Past research has shown that deadlines shape the quality of decisions around FDA drug approvals -e.g., "just-before-deadline" approvals are linked with higher rates of postmarked safety problems (Carpenter, Chattopadhyay et al. 2012 ). Thus, it is possible that scientists may feel that the standard of the quality of the evidence necessary are lowered for Priority rated drugs.
Implications for policy
Overall, these results confirm that contextual factors play a role in selective reporting, with implications for both practice and public policy. First, this paper draws the attention of individual scientists and scientific teams to how the project might tilt the balance of their considerations closer to poor reporting, or more generally, to poor science. Second, this study provides support to the view that private funding can have far reaching implications for the conduct of academic research. Third, my results also have important implications for public policy and any third-parties trying to make sense of the nature or the value of an innovation by looking at scientific publications. From the findings, I
conclude that if transparency is desired it is important to take into account the heterogeneity of projects in term of the source of support and innovativeness of research.
Limitations
Although interesting, this analysis has many limitations. First, the starting sample of this study is based on a unique dataset constructed from the Cochrane Database of Systematic Reviews. Due to the complexities in data collection and limitations in coverage, this dataset includes only certain trials in selected therapeutic areas (and an especially small number in Oncology). It is possible that the associations I observed may not generalize to different disease areas. Yet, past studies have indicated that reporting bias is spread across several indications and drug classes (McGauran, Wieseler et al. 2010 , Downing, Aminawung et al. 2014 .
With regard to the first analysis (institutional support and selective reporting), it is important to note that data on funding and financial ties were extracted from the information contained in the Tables   Table 1 -Descriptive statistics (Full sample used 
